沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察

目的:探讨沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果。方法:选取2014年1月-2016年12月我院收治的非小细胞肺癌患者79例,按照治疗方法的不同分为对照组40例、观察组39例。对照组进行常规非小细胞肺癌治疗,观察组在手术前给予沙利度胺联合吉非替尼靶向治疗后行常规治疗。比较两组临床疗效,6个月、1年生存率,并记录观察组患者不良反应的发生情况。结果:观察组化疗的化疗缓解率(71.79%)显著高于对照组(52.50%)(P0.05)。观察组患者在治疗期间出现了不同程度的白细胞减少、、恶心呕吐、关节痛、脱发、肝功能损伤等不良反应,患者对以上症状均可耐受,给予对症治疗后均自行缓解。观察组患者6个月、1年生存率均显著高于对照组(P0.05)。结论:沙利度胺联合吉非替尼靶向治疗NSCLC患者的疗效较好,能显著提高患者生存率。

Therapeutic Effect of Thalidomide Combined with Gefitinib on Non-small Cell Lung Cancer

ABSTRACT Objective: To explore the clinical efficacy of thalidomide combined with gefitinib in the treatment of non-small cell lung cancer. Methods: Selected 79 NSCLC patients admitted to our hospital from January 2014 to December 2016. All patients were divided into control group (n=40) and observation group (n=39) by treatment methods. The control group received NSCLC routine treatment. The observation group was given thalidomide combined with gefitinib targeted therapy before surgery, then received routine treatment. The clinical efficacy, 6 months and 1 year survival rates between two groups were compared. The incidence of adverse reactions in the obser- vation group was recorded. Results: The chemotherapy remission rate in the observation group (71.79 %) was significantly higher than that in the control group (52.50 %) (P<0.05). The patients in the observation group experienced various adverse reactions such as neu- tropenia, nausea and vomiting, joint pain, hair loss, and liver function impairment during the treatment period. Patients can tolerate the above symptoms, and they all relieve themselves after symptomatic treatment. The 6-month and 1-year survival rates in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Thalidomide combined with gefitinib is effective in the treatment of NSCLC patients and can significantly improve the survival rate of patients. It is worth further study.